News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

SYGNIS Pharma AG Secures Further Financial Resources With New Investors Loan



7/8/2013 9:29:55 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Heidelberg, 8 July 2013 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) today reports on the granting of a loan for a total amount of up to EUR 0.55 million by a group of international investors comprising the Bedford Investment Fund, George Town, Cayman Islands, The Excalibur Investments Fund, George Town, Cayman Islands and Casticapital, S.L., Las Palmas de Gran Canaria, Spain, as well as Mr. Gonzalo Rodríguez-Fraile Díaz, who is a member of the Supervisory Board of SYGNIS Pharma AG. Another member of the Supervisory Board of SYGNIS Pharma AG, Mr. Pedro-Agustín del Castillo Machado, is Chairman of the Board of Directors of Casticapital, S.L.

The loan bears interest at customary market conditions. The loan, which is payable on demand, secures the financing of SYGNIS’ existing operations, according to the present plans, until mid September 2013. The loan is secured and is due for repayment not before the end of 2014.

Under the loan agreement, the international investors may, subject to certain conditions, participate in a possible future capital increase of SYGNIS by subscribing for newly issued SYGNIS shares from the Company's authorized capital.

For further information please contact:

SYGNIS Pharma AG

Pilar de la Huerta

CEO/CFO

Tel: +34-918063089

Email: pdelahuerta@sygnis.es

Disclaimer

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES